Mostrar el registro sencillo del ítem
Intravitreal Bevacizumab for Retinopathy of Prematurity: Another Hit to the Immature Lung?
| dc.contributor.author | Alonso-Ojembarrena, Almudena | |
| dc.contributor.author | Oulego‑Erróz, Ignacio | |
| dc.date.accessioned | 2023-10-10T12:48:18Z | |
| dc.date.available | 2023-10-10T12:48:18Z | |
| dc.date.issued | 2022-12-06 | |
| dc.identifier.issn | 0012-3692 | |
| dc.identifier.uri | http://hdl.handle.net/10498/29411 | |
| dc.description.abstract | Laser photocoagulation has been the standard of treatment of ROP for many years. However, since its introduction in 2007, the use of intravitreal injection of anti-VEGF agents has been incorporated to ROP management. Several trials have shown that anti-VEGF drugs (bevacizumab, ranibizumab) may be superior to laser photocoagulation for type I ROP (zone I [any stage with plus disease] or zone I-stage 3 without plus disease) | es_ES |
| dc.format | application/pdf | es_ES |
| dc.language.iso | eng | es_ES |
| dc.publisher | Elsevier | es_ES |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
| dc.source | Chest. vol. 162, nº 6, December 2022, pp. 1231 - 1232 | es_ES |
| dc.subject | Retinopathy of prematurity (ROP) | es_ES |
| dc.subject | Bevacizumab | es_ES |
| dc.subject | Retinopathy of Prematurity | es_ES |
| dc.title | Intravitreal Bevacizumab for Retinopathy of Prematurity: Another Hit to the Immature Lung? | es_ES |
| dc.type | journal article | es_ES |
| dc.rights.accessRights | open access | es_ES |
| dc.description.physDesc | 2 páginas | es_ES |
| dc.identifier.doi | 10.1016/j.chest.2022.06.032 | |
| dc.type.hasVersion | VoR | es_ES |
Ficheros en el ítem
Este ítem aparece en la(s) siguiente(s) colección(ones)
-
Artículos Científicos [12077]
-
Artículos Científicos INIBICA [1097]
